US Bancorp’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

US Bancorp’s Portfolio VYNT Stock Details VYNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,962	Closed	-$2.88K	–	4195
2023 Q1	$2.88K	Hold	4,962	–	–	﹤0.01%	3683
2022 Q4	$3.49K	Sell	4,962 -1	-0%	-$2	﹤0.01%	3628
2022 Q3	$14K	Hold	4,963	–	–	﹤0.01%	3244
2022 Q2	$23K	Hold	4,963	–	–	﹤0.01%	2983
2022 Q1	$35K	Buy	4,963 +4,803	+3,002%	+$27.9K	﹤0.01%	2801
2021 Q4	$1K	Hold	160	–	–	﹤0.01%	4064
2021 Q3	$2K	Hold	160	–	–	﹤0.01%	3946
2021 Q2	$3K	Hold	160	–	–	﹤0.01%	3781
2021 Q1	$4K	Buy	+160	New	+$4.05K	﹤0.01%	3578
2016 Q4	–	Sell	-1	Closed	–	–	3667
2016 Q3	$0	Buy	+1	New	+$306	﹤0.01%	3646

Other funds holding VYNT

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

US Bancorp's VYNT Position: Q2 2023 in Review

US Bancorp sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2023, closing a stake of 4,962 shares — an estimated $2.88K sold.

US Bancorp first reported a position in VYNT in Q3 2016 and held it in 10 quarters. The position peaked at $35K in Q1 2022. 1 fund tracked by Wall St. Rank holds VYNT as of Q2 2023.

US Bancorp reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
US Bancorp sold 4,962 Vyant Bio, Inc. Common Stock shares in Q2 2023, an estimated $2.88K.
US Bancorp first reported a position in Vyant Bio, Inc. Common Stock in Q3 2016 and held it in 10 quarters.
US Bancorp's Vyant Bio, Inc. Common Stock position peaked at $35K in Q1 2022.
1 fund tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2023.

Based on US Bancorp's 13F filing for Q2 2023, filed 10 Aug 2023.